Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH

Vasculitis

Quality of life

Rituximab and rheumatology practice in the COVID-19 era

How can rheumatologists respond to the challenges associated with rituximab use during the pandemic?

Browse the hub

Anifrolumab for the treatment of lupus

Perspective on the approval of anifrolumab and the importance of endpoints in lupus trials.

Visit the hub

New additions to the Adis Journal Club

A monthly selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

Visit the hub

JAK inhibitor safety

Data summary, expert discussion, & research news on the potential risks associated with JAK inhibitors.

ACR Convergence 2021 highlights

3–9 November: Keep up with the latest news and interviews from the conference.

Visit the conference hub

Febuxostat and cardiovascular risk in people with gout

How will the FAST trial results impact regulatory guidance & clinical practice?

Read the article

Telemedicine in rheumatology

Experts discuss the increasing use of telemedicine in rheumatology during the COVID-19 pandemic.

Browse the hub

Get ready for ACR Convergence 2020

5 – 9 November: Preview the conference with session recommendations and updates on upcoming coverage.

Visit the conference hub

02-04-2018 | Quality of life | Review | Article

How do patients with systemic autoimmune rheumatic disease perceive the use of their medications: A systematic review and thematic synthesis of qualitative research

Haag H et al. BMC Rheumatol 2018; 2: 9. doi: 10.1186/s41927-018-0017-8

Behçet syndrome: a contemporary view

In this review, the authors discuss the emerging, most-recent evidence on the etiology, manifestations and epidemiology of Behçet syndrome [read more].
Nat Rev Rheumatol 2018; 14: 107–119. doi: 10.1038/nrrheum.2017.208

Behçet syndrome: a contemporary view

12-04-2017 | Quality of life | Article

Quality of life of patients treated for giant cell arteritis: a case-control study

Jobard et al postulated that giant cell arteritis (GCA) patients taking high dose corticosteroids had no significant impairment of quality of life (QOL) compared with controls in their study. GCA complications did not seem to have any major impact on QOL.

Clin Rheumatol 2017; advance online publication; doi:10.1007/s10067-017-3619-4

14-01-2016 | Quality of life | Review | Article

Patient-reported outcomes in trials of patients with polymyalgia rheumatica: a systematic literature review

The authors determined that although several patient-reported outcomes have been identified additional work is needed to obtain a better insight into the required outcomes that incorporate the patient’s perspective.

Rheumatol Int 2016;36:897. doi:10.1007/s00296-015-3416-9


More on vasculitis


« Back to main page | ANCA-associated vasculitis | Behçet's disease | Giant cell arteritis | Granulomatosis with polyangiitis | Polymyalgia rheumatica | Takayasu arteritis | Clinical trials | Comorbidities | Diagnosis and screening | Epidemiology | Medications | Pathophysiology | Quality of life


Image Credits